Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. This donation furthers both Lilly and Direct Relief's charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries. (Source: World Pharma News)
Source: World Pharma News - May 5, 2021 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news

Our immune systems blanket the SARS-CoV-2 spike protein with antibodies
The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. In the journal Science, researchers at The University of Texas at Austin describe the finding, which represents good news for designing the next generation of vaccines to protect against variants of the virus or future emerging coronaviruses. (Source: World Pharma News)
Source: World Pharma News - May 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years. (Source: World Pharma News)
Source: World Pharma News - May 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Speeding new treatments
A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-CoV-2. But what if herd immunity is never fully achieved - or if the mutating virus gives rise to hyper-virulent variants that diminish the benefits of vaccination? (Source: World Pharma News)
Source: World Pharma News - May 3, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Moderna announces emergency use listing granted by the World Health Organization for its COVID-19 vaccine
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older. (Source: World Pharma News)
Source: World Pharma News - May 3, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Large collaboration creates cell atlas of COVID-19 pathology
Scientists from several hospitals and research centers have shown what happens in individual cells of patients who died of COVID-19. In a study published in Nature, the researchers describe how infected cells from multiple organs exhibited a range of molecular and genomic changes. They also saw signs of multiple, unsuccessful attempts by the lungs to repair themselves in response to respiratory failure, which is the leading cause of death in COVID-19 patients. (Source: World Pharma News)
Source: World Pharma News - April 30, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra ®
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche's Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19 associated pneumonia. (Source: World Pharma News)
Source: World Pharma News - April 29, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Moderna announces additional investments to increase global supply for COVID-19 vaccine to up to 3 billion doses in 2022
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it is making new funding commitments to increase supply at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its COVID-19 vaccine, (Source: World Pharma News)
Source: World Pharma News - April 29, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Brazilian coronavirus variant likely to be more transmissible and able to evade immunity
Even though more and more vaccines against the coronavirus are being administered all over the world, many countries are still battling with outbreaks and face difficulties providing help to those in need. One of those countries is Brazil. Here, they are facing a massive second wave outbreak, many daily deaths and instances of the health care systems collapsing. (Source: World Pharma News)
Source: World Pharma News - April 28, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx's lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. (Source: World Pharma News)
Source: World Pharma News - April 28, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Hepatitis C drugs multiply effect of COVID-19 antiviral Remdesivir
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19. Published this week in Cell Reports, this finding - from Gaetano Montelione, a professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, and his collaborators at the Icahn School of Medicine at Mount Sinai and the University of Texas at Austin - raises the potential for repurposing available drugs as COVID-19 antivirals in cases where a vaccine isn't practical or effective. (Source: World Pharma News)
Source: World Pharma News - April 27, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

How COVID-19 impacted UK healthcare
Just one third of people in the UK managed to access the hospital care they needed at the peak of the first wave of the Covid-19 pandemic - according to new research from the University of East Anglia. A new study published today looks at the extent to which people managed to access NHS healthcare in April 2020, and as lockdown restrictions eased. (Source: World Pharma News)
Source: World Pharma News - April 26, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands
Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna's COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs. Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna's COVID-19 vaccine, starting in September 2021. (Source: World Pharma News)
Source: World Pharma News - April 26, 2021 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus
The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them. The immune defense is able to recall the pathogens it has encountered previously, on which, for example, the effectiveness of vaccines is based. (Source: World Pharma News)
Source: World Pharma News - April 23, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review
Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume. (Source: World Pharma News)
Source: World Pharma News - April 23, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV, the company's mRNA based COVID-19 vaccine candidate, for the use in Switzerland. (Source: World Pharma News)
Source: World Pharma News - April 22, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Updated results on coronavirus vaccination effectiveness
Several weeks following the publication of the large real-world COVID-19 vaccine effectiveness study by the Clalit Research Institute in Collaboration with Harvard University in the New England Journal of Medicine (NEJM), additional results focusing on vaccine effectiveness in specific sub-populations have now been published. (Source: World Pharma News)
Source: World Pharma News - April 22, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced it is now focusing on bilateral discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC). (Source: World Pharma News)
Source: World Pharma News - April 21, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus. Researchers from the Wellcome Sanger Institute, Newcastle University, University College London, University of Cambridge, EMBL's European Bioinformatics Institute (EMBL-EBI) and their collaborators within the Human Cell Atlas initiative, found raised levels of specific immune cells in asymptomatic people. (Source: World Pharma News)
Source: World Pharma News - April 20, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY ®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a result of the European Commission's (EC) decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17, 2021. (Source: World Pharma News)
Source: World Pharma News - April 20, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Patients who are obese or overweight are at risk for a more severe course of COVID-19
COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mechanical ventilation more often. There is no increased risk of death . These conclusions, for which more than 7,000 patients were studied, appear from international research in eleven countries, including the Netherlands (Radboud university medical center). (Source: World Pharma News)
Source: World Pharma News - April 19, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New COVID-19 vaccine may offer broad protection from coronaviruses
A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing. Vaccines created by UVA Health's Steven L. Zeichner, MD, PhD, and Virginia Tech's Xiang-Jin Meng, MD, PhD, prevented pigs from being becoming ill with a pig model coronavirus, porcine epidemic diarrhea virus (PEDV). (Source: World Pharma News)
Source: World Pharma News - April 19, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. (Source: World Pharma News)
Source: World Pharma News - April 16, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Amgen successfully completes acquisition of Five Prime Therapeutics
Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. (Source: World Pharma News)
Source: World Pharma News - April 16, 2021 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

SARS-CoV-2: New findings on the persistence of neutralizing antibodies
It is an open question to what extent protection against reinfection persists after overcoming a SARS-CoV-2 infection. The "Rhineland Study", a population-based study conducted by DZNE in the Bonn area, is now providing new findings in this regard. Blood samples taken last year indicate that an important component of immunity - the levels of specific neutralizing antibodies against the coronavirus - had dropped in (Source: World Pharma News)
Source: World Pharma News - April 15, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. (Source: World Pharma News)
Source: World Pharma News - April 15, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Massive fragment screen points way to new SARS-CoV-2 inhibitors
New research published in Science Advances provides a template for how to develop directly-acting antivirals with novel modes of action, that would combat COVID-19 by suppressing the SARS-CoV-2 viral infection. The study focused on the macrodomain part of the Nsp3 gene product that SARS-CoV-2 uses to suppress the host cell's natural antiviral response. (Source: World Pharma News)
Source: World Pharma News - April 14, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Johnson & Johnson statement on COVID-19 vaccine
The safety and well-being of the people who use our products is our number one priority. We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine. (Source: World Pharma News)
Source: World Pharma News - April 14, 2021 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
Two new studies, published in The Lancet Infectious Diseases and The Lancet Public Health, found no evidence that people with the B.1.1.7. variant experience worse symptoms or a heightened risk of developing long COVID compared with those infected with a different COVID-19 strain. However, viral load and R number were higher for B.1.1.7., adding to growing evidence that it is more transmissible than the first strain detected in Wuhan, China, in December 2019. (Source: World Pharma News)
Source: World Pharma News - April 13, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). (Source: World Pharma News)
Source: World Pharma News - April 13, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. (Source: World Pharma News)
Source: World Pharma News - April 12, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Pfizer and BioNTech request regulatory agencies expand emergency use of their COVID-19 vaccine to adolescents
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) to expand the use in adolescents 12 to 15 years of age. The companies plan to request similar rulings by other regulatory authorities worldwide in coming days. (Source: World Pharma News)
Source: World Pharma News - April 9, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

COVID-19 causes 'unexpected' cellular response in the lungs
New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly found that a biochemical pathway, known as the immune complement system, is triggered in lung cells by the virus, which might explain why the disease is so difficult to treat. (Source: World Pharma News)
Source: World Pharma News - April 8, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
EMA's safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group. (Source: World Pharma News)
Source: World Pharma News - April 7, 2021 Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news

Clinical trial completion rates decline during COVID-19 pandemic
Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected clinical researchers' ability to finish trials. Study completion rates dropped worldwide between 13% and 23%, depending on the type of research sponsor and geographic location, between April and October 2020. (Source: World Pharma News)
Source: World Pharma News - April 7, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study identifies possible COVID-19 drugs - including several that are FDA-approved
A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases. (Source: World Pharma News)
Source: World Pharma News - April 6, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced positive data for Part A of the Phase 1/2 clinical trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. (Source: World Pharma News)
Source: World Pharma News - April 6, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

COVID-19 convalescent plasma with greater antibody levels is safe and shows promise
Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels of antibodies, according to a new publication by scientists at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network. (Source: World Pharma News)
Source: World Pharma News - April 5, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Prioritizing who gets vaccinated for COVID-19 saves lives
Waiting for your turn can be frustrating, especially when it comes to COVID-19 vaccinations. But prioritizing who receives the limited supply of vaccines available saves lives and reduces spread of infection, according to a study published in the journal PNAS from the University of California, Davis. (Source: World Pharma News)
Source: World Pharma News - April 5, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing that the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. (Source: World Pharma News)
Source: World Pharma News - April 2, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Undetected coronavirus variant was in at least 15 countries before its discovery
A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium. Scientists first discovered it in early December in the United Kingdom, where the highly contagious and more lethal variant is thought to have originated. (Source: World Pharma News)
Source: World Pharma News - April 1, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

COVID-19 survivors might need just one dose of two-part vaccine
A single dose of the Pfizer-BioNTech vaccine for individuals who previously had COVID-19 generates an immunologic response similar to that of individuals receiving the two-dose recommended sequence, according to a Cedars-Sinai study published today by the journal Nature Medicine. (Source: World Pharma News)
Source: World Pharma News - April 1, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

B.1.1.7 variant of COVID-19 spreading rapidly in United States
The faster-spreading B.1.1.7 variant of SARS-CoV-2 first detected in the United Kingdom, the coronavirus that causes COVID-19, is quickly on its way to becoming the dominant variant of the virus in the United States, according to a study from scientists at Scripps Research and the COVID-19 test maker Helix. (Source: World Pharma News)
Source: World Pharma News - March 31, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. (Source: World Pharma News)
Source: World Pharma News - March 31, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

GSK to support manufacture of Novavax' COVID-19 vaccine
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide 'fill and finish' manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. (Source: World Pharma News)
Source: World Pharma News - March 30, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Anti-inflammatory drug protects against lethal inflammation from COVID-19 in animal models
Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory genes has reduced morbidity and mortality in mice infected with SARS-CoV-2, the virus that causes COVID-19. In a study published today in the journal Cell, the team reported that the drug, Topotecan (TPT), inhibited the expression of inflammatory genes in the lungs of mice as late as four days after infection, a finding with potential implications for treatment of humans. (Source: World Pharma News)
Source: World Pharma News - March 30, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Johnson & Johnson announces advance purchase agreement with the African Vaccine Acquisition Trust
Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union's 55 member states with delivery beginning in the third quarter of 2021. (Source: World Pharma News)
Source: World Pharma News - March 29, 2021 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
EMA's human medicines committee (CHMP) has adopted several important recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines in the EU. (Source: World Pharma News)
Source: World Pharma News - March 29, 2021 Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news

BioNTech provides update on vaccine production status at Marburg manufacturing site
BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part of the process, EMA has approved the production of the drug substance, the mRNA, at the Marburg site over the course of this week. (Source: World Pharma News)
Source: World Pharma News - March 26, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Will COVID-19 vaccines need to be adapted regularly?
Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses. Will the same apply to COVID-19 vaccines? In order to gauge whether and to what extent this may be necessary, a team of researchers from Charité - Universitätsmedizin Berlin compared the evolution of endemic 'common cold' coronaviruses with that of influenza viruses. (Source: World Pharma News)
Source: World Pharma News - March 25, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news